Fluoroquinolone-nonsusceptible Streptococcus pneumoniae isolates from a medical center in the pneumococcal conjugate vaccine era

Journal of Microbiology, Immunology and Infection

Volumn 50, Issue 6, 2017, Pages 839-845

  Chen, Hsin Hang ^a   Li, Hsin Chieh ^a   Su, Lin Hui ^a,b   Chiu, Cheng Hsun ^a,b  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Fluoroquinolone; pneumococcal conjugate vaccine; resistance; Streptococcus pneumoniae

Indexed keywords

CEFTRIAXONE; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; LEVOFLOXACIN; MOXIFLOXACIN; PENICILLIN DERIVATIVE; PNEUMOCOCCUS VACCINE; PROTEIN PARC; PROTEIN PARE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; GYRASE INHIBITOR; QUINOLONE DERIVATIVE; VACCINE;

AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CHILD; CLONAL VARIATION; FEMALE; GENE LOCUS; GENE MUTATION; GENOTYPE; HUMAN; MALE; NONHUMAN; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; TAIWAN; ADOLESCENT; ADULT; DISK DIFFUSION; DRUG EFFECT; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; MULTILOCUS SEQUENCE TYPING; PRESCHOOL CHILD; PROSPECTIVE STUDY; SEROTYPE; STREPTOCOCCUS PNEUMONIA; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; DISK DIFFUSION ANTIMICROBIAL TESTS; DNA GYRASE; DNA TOPOISOMERASE IV; DRUG RESISTANCE, BACTERIAL; FEMALE; FLUOROQUINOLONES; HEPTAVALENT PNEUMOCOCCAL CONJUGATE VACCINE; HUMANS; LEVOFLOXACIN; MALE; MIDDLE AGED; MULTILOCUS SEQUENCE TYPING; PNEUMONIA, PNEUMOCOCCAL; PROSPECTIVE STUDIES; SEROGROUP; STREPTOCOCCUS PNEUMONIAE; TOPOISOMERASE II INHIBITORS; VACCINES, CONJUGATE; YOUNG ADULT;

EID: 85006705736     PISSN: 16841182     EISSN: 19959133     Source Type: Journal    
DOI: 10.1016/j.jmii.2016.05.003     Document Type: Article

References (32)

1. Chen, D.K., McGeer, A., de Azavedo, J.C., Low, D.E., Decreased susceptibility of Streptococcus pneumonia to fluoroquinolones in Canada. N Engl J Med 341 (1999), 233–239.
2. Linares, J., de la Campa, A.G., Pallares, R., Fluoroquinolone resistance in Streptococcus pneumoniae. N Engl J Med 341 (1999), 1546–1547.
3. von Gottberg, A., Klugman, K.P., Cohen, C., Govind, C., Sturm, A.W., Klugman, K.P., Emergence of levofloxacin-non-susceptible Streptococcus pneumoniae and treatment for multidrug-resistant tuberculosis in children in South Africa: a cohort observational surveillance study. Lancet 371 (2008), 1108–1113.
4. Oh, W.S., Suh, J.Y., Song, J.H., Ko, K.S., Jung, S.I., Peck, K.R., et al. Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae from Asian countries: ANSORP Study. Microb Drug Resist 10 (2004), 37–42.
5. McGee, L., Goldsmith, C.E., Klugman, K.P., Davidson, R., Cavalcanti, R., Brunton, J.L., et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 346 (2002), 747–750.
6. Kang, C.I., Song, J.H., Kim, S.H., Chung, D.R., Peck, K.R., Thamlikitkul, V., et al. Association of levofloxacin resistance with mortality in adult patients with invasive pneumococcal diseases: a post hoc analysis of a prospective cohort. Infection 41 (2013), 151–157.
7. Bowker, K.E., Garvey, M.I., Noel, A.R., Tomaselli, S.G., Macgowan, A.P., Comparative antibacterial effects of moxifloxacin and levofloxacin on Streptococcus pneumoniae strains with defined mechanisms of resistance: impact of bacterial inoculum. J Antimicrob Chemother 68 (2013), 1130–1138.
8. Wei, S.H., Chiang, C.S., Chen, C.L., Chiu, C.H., Pneumococcal disease and use of pneumococcal vaccines in Taiwan. Clin Exp Vaccine Res 4 (2015), 121–129.
9. Clinical and Laboratory Standards Institute (CLSI), Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard. 10th Ed. CLSI document M02–A10.Wayne (PA). 2009, Clinical and Laboratory Standards Institute.
10. Clinical and Laboratory Standards Institute (CLSI), Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard. 11th Ed. CLSI document M02–A11.Wayne (PA). 2012, Clinical and Laboratory Standards Institute.
11. Pai, R., Gertz, R.E., Beall, B., Sequential multiplex PCR approach for determining capsular serotypes of Streptococcus pneumoniae isolates. J Clin Microbiol 44 (2006), 124–131.
12. Jin, P., Kong, F., Xiao, M., Oftadeh, S., Zhou, F., Liu, C., et al. First report of putative Streptococcus pneumoniae serotype 6D among nasopharyngeal isolates from Fijian children. J Infect Dis 200 (2009), 1375–1380.
13. Yun, K.W., Cho, E.Y., Hong, K.B., Choi, E.H., Lee, H.J., Streptococcus pneumoniae type determination by multiplex polymerase chain reaction. J Korean Med Sci 26 (2011), 971–978.
14. Enright, M.C., Spratt, B.G., A multilocus sequence typing scheme for Streptococcus pneumoniae: identification of clones associated with serious invasive disease. Microbiology 144 (1998), 3049–3060.
15. Broskey, J., Coleman, K., Gwynn, M.N., McCloskey, L., Traini, C., Voelker, L., et al. Efflux target mutations as quinolone resistance mechanisms in clinical isolates of Streptococcus pneumoniae. J Antimicrob Chemother 45:Suppl. 1 (2000), 95–99.
16. Kim, S.H., Song, J.H., Chung, D.R., Thamlikitkul, V., Yang, Y., Wang, H., et al. Changing trends in antimicrobial resistance and serotypes of Streptococcus pneumoniae isolates in Asian countries: an Asian Network for Surveillance of Resistant Pathogens (ANSORP) study. Antimicrob Agents Chemother 56 (2012), 1418–1426.
17. CF, Li, Liu, M.F., Shi, Z.Y., Hsueh, P.R., Liao, C.H., Jang, T.N., et al. Changing trends in antimicrobial susceptibility of Streptococcus pneumoniae isolates in Taiwan, 2006–2007. J Microbiol Immunol Infect 45 (2012), 305–310.
18. Hsieh, Y.C., Chang, L.Y., Huang, Y.C., Lin, H.C., Huang, L.M., Hsueh, P.R., Circulation of international clones of levofloxacin non-susceptible Streptococcus pneumoniae in Taiwan. Clin Microbiol Infect 16 (2010), 973–978.
19. Costelloe, C., Metcalfe, C., Lovering, A., Mant, D., Hay, A.D., Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis. BMJ, 340, 2010, c2096.
20. Tsai, H.Y., Lauderdale, T.L., Wang, J.T., Chen, Y.S., Liu, J.W., Huang, J.H., et al. Updated antibiotic resistance and clinical spectrum of infections caused by Streptococcus pneumoniae in Taiwan: emphasis on risk factors for penicillin nonsusceptibilities. J Microbiol Immunol Infect 46 (2013), 345–351.
21. Hsueh, P.R., Liu, Y.C., So, J., Liu, C.Y., Yang, P.C., Luh, K.T., Mycobacterium tuberculosis in Taiwan. J Infect 52 (2006), 77–85.
22. Mandell, L.A., Wunderink, R.G., Anzueto, A., Bartlett, J.G., Campbell, G.D., Dean, N.C., et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44 (2007), S27–S72.
23. Kuo, S.C., Shih, S.M., Lauderdale, T.L., Chen, Y.C., Hsiung, C.A., Fluoroquinolone prescribing in Taiwan, 2000 to 2010. J Microbiol Immunol Infect, 48, 2015, S103.
24. Dunais, B., Bruno, P., Touboul, P., Degand, N., Sakarovitch, C., Fontas, E., et al. Impact of the 13-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae among children attending group daycare in southeastern France. Pediatr Infect Dis J 34 (2015), 286–288.
25. Pletz, M.W., McGee, L., Jorgensen, J., Beall, B., Facklam, R.R., Whitney, C.G., et al. Levofloxacin-resistant invasive Streptococcus pneumoniae in the United States: evidence for clonal spread and the impact of conjugate pneumococcal vaccine. Antimicrob Agents Chemother 48 (2004), 3491–3497.
26. de la Campa, A.G., Ardanuy, C., Balsalobre, L., Pérez-Trallero, E., Marimón, J.M., Fenoll, A., et al. Changes in fluoroquinolone-resistant Streptococcus pneumoniae after 7-valent conjugate vaccination. Spain J Emerg Infect Dis 15 (2009), 905–911.
27. Wei, S.H., Chiang, C.S., Chiu, C.H., Chou, P., Lin, T.Y., Pediatric invasive pneumococcal disease in Taiwan following a national catch-up program with the 13-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 34 (2015), e71–e77.
28. Loo, J.D., Conklin, L., Fleming-Dutra, K.E., Deloria, K.M., Park, D.E., Kirk, J., et al. Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on prevention of pneumonia. Pediatr Infect Dis J 33 (2014), S140–S151.
29. Ho, P.L., Chiu, S.S., Law, P.Y., Chan, E.L., Lai, E.L., Chow, K.H., Increase in the nasopharyngeal carriage of non-vaccine serogroup 15 Streptococcus pneumoniae after introduction of children pneumococcal conjugate vaccination in Hong Kong. Diagn Microbiol Infect Dis 81 (2015), 145–148.
30. Lexau, C.A., Lynfield, R., Danila, R., Pilishvili, T., Facklam, R., Farley, M.M., et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 294 (2005), 2043–2051.
31. Kaplan, S.L., Center, K.J., Barson, W.J., Ling-Lin, P., Romero, J.R., Bradley, J.S., et al. Multicenter surveillance of Streptococcus pneumoniae isolates from middle ear and mastoid cultures in the 13-valent pneumococcal conjugate vaccine era. Clin Infect Dis 60 (2015), 1339–1345.
32. Loughlin, A.M., Hsu, K., Silverio, A.L., Marchant, C.D., Pelton, S.I., Direct and indirect effects of PCV13 on nasopharyngeal carriage of PCV13 unique pneumococcal serotypes in Massachusetts’ children. Pediatr Infect Dis J 33 (2014), 504–510.